With the COVID-19 pandemic moving through the country, it is important for clinicians to have the most up-to-date information. Join this session with Dr. Peter Libby to learn about the cardiovascular complications of COVID-19 and how you can help patients facing these issues.

Peter Libby, MD

Cardiovascular Specialist, Brigham and Women's Hospital, Boston, MA; Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA

Erin Bohula, MD, DPhil

Cardiac Intensivist, Brigham & Women's Hospital; Investigator, TIMI Study Group; Instructor, Harvard Medical School, Boston, MA

The most recent CDC report estimates an asthma prevalence of 7.9% in the U.S. Although patients with severe asthma make up only 3–10% of the total asthma population, they account for a substantial proportion of asthma morbidity and health expenditures. With the emergence of new biologic therapies targeting cytokines involved in pathogenesis of asthma, severe asthma is no longer considered the “refractory” disease of yesteryear. This session offers guidance on distinguishing characteristics pertinent to individualizing asthma treatment, such as subtype, phenotype, and endotype as well as biomarkers and other measures of assessment that identify patients with severe eosinophilic asthma. Using expert guidelines, the faculty will discuss how to apply these individual factors to treatment management and alleviate the burden of asthma in your practice.

Christopher H. Fanta, MD

Professor of Medicine, Harvard Medical School, Boston, MA; Director, Partners Asthma Center, Member, Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston, MA

Gerald W. Smetana, MD

Professor of Medicine, Harvard Medical School, Boston, MA; Clinician Educator, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA

Supported by GlaxoSmithKline

Is influenza going viral in your practice? This session on influenza diagnosis and management will improve how you respond when annual fluctuations in vaccine efficacy expose your patients to risk of serious illness. Through interactive patient cases, the faculty will demonstrate how to identify and treat patients with suspected influenza, including patients at high risk for complications. These practical, evidence-based strategies will help you to use antiviral medications effectively and reduce the burden of influenza.

Paul E. Sax, MD

Clinical Director, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; Professor of Medicine, Harvard Medical School, Boston, MA

Daniel Solomon, MD

Associate Physician, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine; Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine

Supported by Genentech

These troubling times require communication among specialists and primary care. In this COVID-19 panel, primary care and infectious disease faculty will team up to discuss the most pressing and frequently asked questions about this disease and its complications.

Frank J. Domino, MD

Professor, Family Medicine and Community Health, University of Massachusetts Medical School, Worcester, MA

Paul E. Sax, MD

Clinical Director, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; Professor of Medicine, Harvard Medical School, Boston, MA

Laila Woc-Colburn, MD

Associate Professor, Section of Infectious Diseases, Department of Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences.

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine, Harvard Medical School; Director, Division of CME, Beth Israel Medical Center, Beth Isreal Deaconess Medical Center, Boston, MA

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine; Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine

Supported by Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Chronic kidney disease is common, yet many clinicians find it intimidating to manage. This session will give you the tools that you need to identify renal disease, recognize which patients are at risk for a decline in renal function, and practice the components of care.

Melanie Hoenig, MD

Associate Professor, Harvard Medical School, Boston, MA